

## BUSINESS UPDATE - FOURTH QUARTER 2014

- **Cash & cash equivalents and liquid investments of €32.8 million as of December 31<sup>st</sup>, 2014**
- **ProCervix phase 2 study enrollment completed ahead of schedule**
- **Genticel wins the Deloitte Technology Fast 50 “Biotech d’Avenir” for 2014**
- **Post quarter close news: ProCervix phase 2 clinical study to continue as planned after 2<sup>nd</sup> review by DSMB**

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its cash & cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014.

### Financial highlights – Fourth quarter 2014

As of December 31<sup>st</sup>, 2014, Genticel's net cash & cash equivalents and liquid investments position was €32.8 million (vs. €35.3 million on September 30<sup>th</sup>, 2014), fully in line with the company's expectations for these items.

Given the current development stage of its therapeutic vaccines candidates and the company's value-creation strategy for these assets, Genticel has as of yet no revenue to report.


### Business highlights – Fourth quarter 2014

#### **239 patients enrolled ahead of schedule in the ProCervix phase 2 study**

With the last patient enrolled on November 10<sup>th</sup>, 2014, Genticel completed the enrollment at least four months in advance, reaching yet another significant milestone in the ProCervix development program.

#### **Genticel wins the 2014 Deloitte Technology Fast 50 “Biotech d’Avenir” (*Most Promising Biotech*) award for SW France**

The Deloitte Technology Fast 50 program recognizes fast-growing innovative technology companies. For its Life Sciences awards, growth is measured by the amount of capital raised during the financial year 2013. This trophy is a recognition of Genticel's strategy that includes giving the company the financial means necessary for the clinical development of its innovative candidate drugs.



**Post quarter close news: ProCervix phase 2 trial to continue as planned after 2<sup>nd</sup> DSMB review on January 22<sup>nd</sup>, 2015**

The Data and Safety Monitoring Board (DSMB), an independent committee of experts that monitors safety data every six months during the study, completed its second safety assessment of the phase 2 clinical study with ProCervix and unanimously recommended the continuation of the trial without any modification. The DSMB had previously made the same recommendation during its first review on July 1<sup>st</sup>, 2014.

**About Genticel**

*Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.*

*Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.*

*Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.*

*Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.*

*For more information, please visit Genticel's website [www.genticel.com](http://www.genticel.com)*



**CONTACT GENTICEL**

Benedikt Timmerman  
Chief Executive Officer  
[investors@genticel.com](mailto:investors@genticel.com)

**USA INVESTOR CONTACT**

Brian Stollar  
Tel.: +1 (212) 915 2577  
[bstollar@lifesciadvisors.com](mailto:bstollar@lifesciadvisors.com)

**INVESTOR CONTACT**

Corinne Puissant  
Tel.: +33 (0)1 53 67 36 77  
[cpuissant@actus.fr](mailto:cpuissant@actus.fr)

**PRESS CONTACT**

Alexandra Prisa  
Tel.: +33 (0)1 53 67 36 90  
[aprisa@actus.fr](mailto:aprisa@actus.fr)